Category: Federal Forum Posters
Purpose: Statin intolerance has been reported in about 10-15% of patients who are started on statin therapy. Use of nondaily doses of a statin has been proposed as a strategy to cope with the challenge of achieving LDL-C reduction in patients with statin intolerance. The objective of this study is to examine the efficacy, compliance, and tolerability of rosuvastatin and atorvastatin for patients on non-daily dosing regimens (every other day, 2-3 times a week, or once weekly).
Methods: This study has been exempted by the Institutional Review Board. The electronical patient record system will be used to identify patients who are on alternative statin dosing regimens. The following data will be collected: demographics (age, weight), duration of alternative dosing regimen, lipid panel, other cholesterol-lowering medications, if the patient is followed by an ambulatory care pharmacist, hepatic function, CPK levels, refill history, and if the patient reached an LDL-C goal of <100 mg/dL or other defined goal by the provider. All data will be recorded without patient identifiers and maintained confidentially. To evaluate efficacy, the difference between LDL-C levels from starting an alternative dosing statin to at least 4 weeks after starting the alternative dosing statin will be calculated. To evaluate tolerability, the patient’s medical record will be reviewed to determine if there is documentation of nontolerance or a reported adverse drug reaction to the alternative dosing statin. To evaluate compliance, the patient’s refill history will be evaluated. To be considered compliant, a patient must refill his or her medication, at least 80% of the time, within the day supply indicated on the prescription.
Results: not applicable
Conclusion: not applicable
Jay Patel– Pharmacy Resident, James J Peters VA Medical Center, Piscataway, NJ